|
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Jun 11, 2009
|
10.7 KB
|
| |
SAN FRANCISCO, June 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's disease.
The international, d...
|
|
|
Medivation to Present at 8th Annual Needham Life Sciences Conference
Jun 4, 2009
|
7.7 KB
|
| |
SAN FRANCISCO, June 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 8th Annual Needham Life Sciences Conference on Thursday, June 11, at 10:30 a.m. Eastern Time at the New York Palace Hotel.
Dr. Hung will prov...
|
|
|
Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
Jun 2, 2009
|
12.0 KB
|
| |
SAN FRANCISCO, June 2, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new clinical results from a Phase 1-2 trial evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant prostate cancer (CRPC) patients. The new findings, which include da...
|
|
|
Medivation Announces Pricing of Public Offering
May 27, 2009
|
7.7 KB
|
| |
SAN FRANCISCO, May 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share. The company expects to complete the sale of these shares on or about June 2, 2009. The company has gr...
|
|
|
Medivation Announces Offering of 2,750,000 Shares of Common Stock
May 26, 2009
|
7.7 KB
|
| |
SAN FRANCISCO, May 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will initiate, subject to market conditions, an offering of 2,750,000 shares of common stock under a shelf registration statement on file with the Securities and Exchange Commission. It is currently anticipated that ...
|
|
|
Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
May 21, 2009
|
9.3 KB
|
| |
SAN FRANCISCO, May 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that additional clinical results from a Phase 1-2 clinical trial involving 140 men with advanced prostate cancer evaluating MDV3100, a next-generation androgen receptor antagonist, will be presented in an oral session at the...
|
|
|
Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
May 13, 2009
|
7.7 KB
|
| |
SAN FRANCISCO, May 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference on Wednesday, May 20 in New York.
Dr. Hung will provide an overview of Medivati...
|
|
|
Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
May 11, 2009
|
16.8 KB
|
| |
SAN FRANCISCO, May 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the first quarter ended March 31, 2009.
"We continue to make significant progress with both of our product candidates -- Dimebon in patients with Alzheimer's and Huntington...
|
|
|
Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
May 4, 2009
|
7.8 KB
|
| |
SAN FRANCISCO, May 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss first quarter 2009 financial results and provide a general business update on Monday, May 11, 2009, at 4:30 p.m. Eastern Time. A press release for the...
|
|
| |
61st American Academy of Neurology (AAN) Annual Meeting Poster Session VIII
Apr 30, 2009
|
82.8 KB
|
| |
61st American Academy of Neurology (AAN) Annual Meeting Poster Session VI
Apr 30, 2009
|
69.0 KB
|
|
Medivation Announces Upcoming Scientific Presentations at Medical Conferences
Apr 23, 2009
|
10.0 KB
|
| |
SAN FRANCISCO, April 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced several presentations at upcoming medical conferences that will feature its investigational drugs MDV3100 and Dimebon.
MDV3100
2009 American Urological Association (AUA) Annual Meeting, April 25-30, Chicago
-- Po...
|
|
|
Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease
Apr 15, 2009
|
12.0 KB
|
| |
NEW YORK and SAN FRANCISCO, April 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pfizer (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) today announced the initiation of a 12-month, Phase 3 clinical trial of the investigational drug Dimebon. The study, known as CONCERT, is designed to evaluate the safety and efficacy of Dimebon when ad...
|
|
|
Medivation Announces Publication in Science Describing MDV3100's Novel and Potent Anti-Androgen Properties
Apr 7, 2009
|
12.5 KB
|
| |
SAN FRANCISCO, April 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced publication of an article in the April 9, 2009, issue of Science Express, the online version of the journal Science, presenting the discovery and novel mechanism of action of MDV3100, the Company's androgen receptor antagon...
|
|
|
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Mar 18, 2009
|
10.7 KB
|
| |
SAN FRANCISCO, March 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has received written permission from the U.S. Food and Drug Administration (FDA) to begin a pivotal Phase 3 trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant...
|
|
|
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Mar 16, 2009
|
18.2 KB
|
| |
SAN FRANCISCO, March 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the fourth quarter and year ended December 31, 2008.
"We had a very productive 2008 and are looking forward to an equally exciting 2009. We have made excellent progress a...
|
|
|
Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
Mar 9, 2009
|
7.9 KB
|
| |
SAN FRANCISCO, March 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss fourth quarter and year-end 2008 financial results and provide a general business update on Monday, March 16, 2009, at 4:30 p.m. Eastern Time. A pres...
|
|
| |
Poster Presentation at ASCO 2009 Genitourinary Cancers Symposium
Feb 27, 2009
|
373.5 KB
|
|
Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Feb 25, 2009
|
13.0 KB
|
| |
SAN FRANCISCO, Feb 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients. The new efficacy...
|
|
|
Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
Feb 24, 2009
|
8.4 KB
|
| |
SAN FRANCISCO, Feb 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference and webcast of a slide presentation on Wednesday, February 25, at 4:30 p.m. Eastern Time to discuss new efficacy and safety data from the ongoing Phase 1-2 clinical trial of the Company's n...
|
|
|
The press releases may contain historical information and may no longer be accurate. Medivation disclaims any responsibility to update such information.
|
 Briefcase
 Download Library
 Email Alerts
 RSS News Feeds
Amanda Mason
WeissComm Partners
1251 6th Ave.
Suite 3500
New York, NY 10020
Phone: 212-301-7221
Fax: 212-867-3249
For a high resolution copy of our logo (eps file), click here.
|
